2.5.5.1: Angiotensin-converting enzyme inhibitors

Part of chapter 2 Cardiovascular System, section 2.5 Hypertension and heart failure

High-level prescribing trends for Angiotensin-converting enzyme inhibitors (BNF section 2.5.5.1) across Tower Hill Partnership for the last five years. You can explore prescribing trends for this section by Sub-ICB Location, or learn more about this site.

View all matching dm+d items.

No prescriptions found.

Do you need help with your analysis? Don't forget to check the FAQ page, and get in touch if you have questions.

Chemicals

Captopril (0205051F0)
Cilazapril (0205051E0)
Co-zidocapt (Hydrochlorothiazide/captopril) (0205051G0)
Enalapril maleate (0205051I0)
Enalapril maleate with diuretic (0205051H0)
Fosinopril sodium (0205051J0)
Imidapril hydrochloride (0205051W0)
Lisinopril (0205051L0)
Lisinopril with diuretic (0205051K0)
Moexipril hydrochloride (0205051C0)
Perindopril arginine (0205051Y0)
Perindopril arginine with diuretic (0205051Z0)
Perindopril erbumine (0205051M0)
Perindopril erbumine with diuretic (0205051N0)
Perindopril tosilate (0205051AA)
Perindopril tosilate/indapamide (0205051AB)
Perindopril with calcium channel blocker (0205051AC)
Quinapril hydrochloride (0205051Q0)
Quinapril hydrochloride with diuretic (0205051P0)
Ramipril (0205051R0)
Ramipril with calcium channel blocker (0205051S0)
Trandolapril (0205051U0)
Trandolapril with calcium channel blocker (0205051V0)
Feedback